BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 26580417)

  • 1. Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.
    Reznicek L; Bolz M; Garip A; Kampik A; Kernt M; Mayer WJ
    Curr Eye Res; 2016 Aug; 41(8):1082-1086. PubMed ID: 26580417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
    Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
    Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
    Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
    Lee J; Moon BG; Cho AR; Yoon YH
    Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting.
    Hrarat L; Fajnkuchen F; Boubaya M; Lévy V; Sarda V; Grenet T; Nghiem-Buffet S; Chaine G; Giocanti-Auregan A
    Ophthalmologica; 2016; 236(4):207-214. PubMed ID: 27898414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP; Mitkute D; Porter G; Vayalambrone D
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
    Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
    Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
    Hsieh YT; Alam MN; Le D; Hsiao CC; Yang CH; Chao DL; Yao X
    Ophthalmol Retina; 2019 Oct; 3(10):826-834. PubMed ID: 31227330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
    Chang CK; Cheng CK; Peng CH
    Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Foveal Microvascular Integrity Association With Anti-VEGF Treatment Response for Diabetic Macular Edema.
    Huang WH; Lai CC; Chuang LH; Huang JC; Wu CH; Lin YT; Yeung L
    Invest Ophthalmol Vis Sci; 2021 Jul; 62(9):41. PubMed ID: 34323921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.